Business Wire

Deel Surpasses $1 Billion Run Rate, Signaling a New Era in Global HR

Share

Leading payroll and HR company Deel announced today that it surpassed a $1 billion run rate in Q1 2025 — a significant milestone achieved in just six years since its founding. This accomplishment underscores Deel’s rapid growth, global scale, and unwavering commitment to enabling the global future of work.

Financial snapshot:

  • Deel crossed $1 billion run rate in Q1 2025 and has continued to grow in April & May
    • It has achieved 75% year on year revenue growth, April 2024-2025.
  • Deel has been profitable since Q3 2023 and has not raised money since 2022. In Q1 2025 it achieved double digit EBITDA margin growth.
  • It has achieved 164% year on year growth across its HR and payroll products, April 2024-2025.

With a customer base exceeding 35,000 companies and 1.25m workers across 150+ countries, Deel has emerged as a foundational platform for modern workforce management.

The company’s integrated product suite and owned infrastructure has reshaped how organizations hire, pay, and manage employees. It offers a unified product platform - eliminating the traditional patchwork of providers many companies used previously - as well as white label and unbundled services, driving long-term growth diversification.

“When I first met Deel, there were 10 people with a big idea, and now they’re powering global teams at a massive scale,” said Anish Acharya, General Partner at Andreessen Horowitz and Board Member at Deel. “Alex and Shuo continue to execute on their vision, methodically building a platform that reduces the complexity of global hiring and enables companies to onboard talent anywhere in the world with speed and confidence. As a result, Deel has become the default infrastructure for global work. Their product velocity and early bet on AI have unlocked tools that make global work simpler and more accessible for customers everywhere.”

“Reaching a $1 billion run rate is a reflection of the trust our customers have put in us,” said Alex Bouaziz, Co-founder and CEO of Deel. “From day one, we believed the future of work demanded a new kind of infrastructure — one that was global, flexible, and obsessed with quality. We’re proud of this milestone, but we’re even more excited about what’s next. Our work has only just begun.”

About Deel

Deel is the all-in-one payroll and HR platform for global teams. Built for the way the world works today, Deel combines HRIS, payroll, compliance, benefits, performance, IT asset equipment management into one seamless platform. With AI-powered tools and a fully owned payroll infrastructure, Deel supports every worker type in 150+ countries—helping businesses scale smarter, faster, and more compliantly. Discover how Deel makes global work simple at deel.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250602672874/en/

Contacts

press@deel.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Special Seminar Paves the Way for European Dairy Brands to Enter China ’ s Special Food Market Under New Rules5.6.2025 05:50:00 EEST | Press release

CCIC Europe Food Test Co., Ltd. (CCIC EFT) is stepping up efforts to help more European companies access China’s infant formula market. On June 25–26, CCIC EFT will host a targeted seminar in Wageningen, the Netherlands, focused on regulatory updates and market access for producers of infant formula, older infant and toddler milk-based formula, and food for special medical purposes (FSMP). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250604444992/en/ CCIC Europe Food Test Co., Ltd. (CCIC EFT) and Technology Innovation Center of Special Food, State Administration of Market Regulation (TISF, SAMR) in the Netherlands. Co-organized with the Technology Innovation Center of Special Food, State Administration of Market Regulation (TISF, SAMR), the seminar is designed for professionals familiar with Chinese regulations and seeking the latest updates on standards, product registration, and market trends. Attendees will benefit from

Belkin Unveils New Gaming Portfolio Featuring Power-Packed Charging Accessories and Gaming Essentials5.6.2025 02:00:00 EEST | Press release

Belkin, a leading consumer electronics brand for over 40 years, today announced its entry into the gaming accessories space with the launch of a new lineup designed to be compatible with the highly anticipated Nintendo Switch 2. Built on decades of experience in power, connectivity and device protection, and released under Belkin’s innovation-focused Future Ventures category, this marks the company’s first collection of products tailored specifically for the gaming community. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250604528148/en/ Belkin’s lineup of Nintendo Switch 2 accessories Belkin is “Leveling up your play” – bringing a new level of reliability to the gaming ecosystem that differentiates through premium materials, timeless design, and in-house engineering. The new range includes elevated accessories designed to enhance the Nintendo Switch 2 experience, featuring on-the-go charging solutions, audio gear, robust s

Biocytogen and Nanjing Chia Tai Tianqing Announce IND Approval in China for Co-Developed Anti-IGF-1R Antibody NTB003 (BCG009)5.6.2025 02:00:00 EEST | Press release

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”, HKEX: 02315) and Nanjing Chia Tai Tianqing Pharmaceutical Co., Ltd. (“NJCTTQ”) announced that NTB003 (formerly BCG009), a co-developed injectable drug candidate, has received the Investigational New Drug (IND) approval from the National Medical Products Administration (NMPA). The approved indication is Thyroid Eye Disease (TED). About NTB003 Injection NTB003 is a second-generation fully human anti-IGF-1R monoclonal antibody co-developed by Biocytogen and Nanjing Chia Tai Tianqing. Antibody discovery and optimization were completed by Biocytogen using its proprietary RenMab™ fully human antibody discovery platform, while Nanjing Chia Tai Tianqing was responsible for CMC process development, GLP-compliant toxicology studies, and IND application. Compared with first-generation approved anti-IGF-1R therapeutics, NTB003 demonstrates enhanced molecular affinity, improved druggability, and an extended half-life. In vitro studies ha

New Potential Treatment Strategy for Brain Metastases and Leptomeningeal Disease: HER3-DXd Shows Promising Results in the Phase II TUXEDO-3 Study for Patients With Limited Therapeutic Options4.6.2025 21:19:00 EEST | Press release

Leading international medical research company, MEDSIR announced today the positive results of the TUXEDO-3 trial at the American Society of Clinical Oncology (ASCO) Annual Meeting 2025. This phase II study funded by Daiichi Sankyo and Merck, known as MSD outside of the United States and Canada, evaluates the efficacy and safety of patritumab deruxtecan (HER3-DXd) in patients with active brain metastases and leptomeningeal disease, serious complications associated with advanced stages of the cancer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250604087994/en/ Dr. Matthias Preusser during Oral Presentation of TUXEDO-3 at ASCO 2025 The study was carried out to evaluate HER3-DXd in patients with metastatic breast cancer (mBC) and advanced non-small cell lung cancer (aNSCLC) with active brain metastases, and patients with leptomeningeal disease from solid tumors. This is an antibody-drug conjugate to target HER3, a protein re

QPS Celebrates 30 th Anniversary4.6.2025 19:00:00 EEST | Press release

QPS Holdings, LLC (QPS), an award-winning contract research organization (CRO) focused on bioanalytics and clinical trials, is celebrating its 30-year anniversary in 2025. Founded by Dr. Benjamin Chien in 1995 to provide high-quality bioanalytical liquid chromatography with tandem mass spectrometry (LC-MS/MS) contract services, QPS is now recognized as a global leader in contract research. Over the past 30 years, the company has grown from a single office in Delaware, USA to a widely respected, global, full-service CRO with 8 locations spread across the US, EU, Asia, India and Australia, a clinical trial network of over 700 sites and an increased focus on leveraging the power of AI to accelerate clinical trials. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250604778675/en/ Dr. Benjamin Chien founder and CEO of QPS Holdings, LLC. Over the years, QPS has grown from a small molecule bioanalysis shop of three people to a globa

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye